Low incidence of new biochemical hypogonadism after intensity modulated radiation therapy for prostate cancer

Stephanie Markovina, Débora Cristina Weschenfelder, Hiram Gay, Audrey McCandless, Bethany Carey, Todd DeWees, Nels Knutson, Jeff Michalski

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: To evaluate serum testosterone and the incidence of biochemical hypogonadism in men treated with intensity modulated radiation therapy (IMRT) for prostate cancer. Methods and materials: Serum testosterone was evaluated prospectively in 51 men at pretreatment and at 6-month time points for 2 years posttreatment with IMRT for prostate cancer. Forty-one patients (80%) were treated with definitive intent and 10 patients with postprostatectomy radiation to median total doses of 7380 cGy and 6480 cGy, respectively. No patients received hormone therapy within 12 months of any serum testosterone value. Biochemical hypogonadism was defined as a total serum testosterone level ≤. 300 ng/dL. Incidental testicular dose was calculated using planning software when computed tomography information was available (n = 21) and using a published method of estimation when not available (n = 24), and was available for 45 patients. Results: A statistically significant decrease in testosterone, though small in magnitude, was seen at 6 months after completion of therapy, with no significant difference by 1 year after completion of therapy. There was no increase in biochemical hypogonadism after IMRT. Below-normal pretreatment testosterone was not associated with a transient decrease. Estimated cumulative testicular dose, including dose from daily imaging, was not associated with a change in testosterone, nor was radiation therapy prescription dose or treatment intent (postoperative vs definitive). Conclusions: The mild transient decrease in serum testosterone following IMRT monotherapy for prostate cancer is not associated with new biochemical hypogonadism.

Original languageEnglish (US)
Pages (from-to)430-436
Number of pages7
JournalPractical Radiation Oncology
Volume4
Issue number6
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Hypogonadism
Testosterone
Prostatic Neoplasms
Radiotherapy
Incidence
Serum
Therapeutics
Prescriptions
Software
Tomography
Hormones
Radiation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Low incidence of new biochemical hypogonadism after intensity modulated radiation therapy for prostate cancer. / Markovina, Stephanie; Weschenfelder, Débora Cristina; Gay, Hiram; McCandless, Audrey; Carey, Bethany; DeWees, Todd; Knutson, Nels; Michalski, Jeff.

In: Practical Radiation Oncology, Vol. 4, No. 6, 01.01.2014, p. 430-436.

Research output: Contribution to journalArticle

Markovina, S, Weschenfelder, DC, Gay, H, McCandless, A, Carey, B, DeWees, T, Knutson, N & Michalski, J 2014, 'Low incidence of new biochemical hypogonadism after intensity modulated radiation therapy for prostate cancer', Practical Radiation Oncology, vol. 4, no. 6, pp. 430-436. https://doi.org/10.1016/j.prro.2014.02.004
Markovina, Stephanie ; Weschenfelder, Débora Cristina ; Gay, Hiram ; McCandless, Audrey ; Carey, Bethany ; DeWees, Todd ; Knutson, Nels ; Michalski, Jeff. / Low incidence of new biochemical hypogonadism after intensity modulated radiation therapy for prostate cancer. In: Practical Radiation Oncology. 2014 ; Vol. 4, No. 6. pp. 430-436.
@article{b07e20f5eeb445dea0fd22a27eedc5d5,
title = "Low incidence of new biochemical hypogonadism after intensity modulated radiation therapy for prostate cancer",
abstract = "Purpose: To evaluate serum testosterone and the incidence of biochemical hypogonadism in men treated with intensity modulated radiation therapy (IMRT) for prostate cancer. Methods and materials: Serum testosterone was evaluated prospectively in 51 men at pretreatment and at 6-month time points for 2 years posttreatment with IMRT for prostate cancer. Forty-one patients (80{\%}) were treated with definitive intent and 10 patients with postprostatectomy radiation to median total doses of 7380 cGy and 6480 cGy, respectively. No patients received hormone therapy within 12 months of any serum testosterone value. Biochemical hypogonadism was defined as a total serum testosterone level ≤. 300 ng/dL. Incidental testicular dose was calculated using planning software when computed tomography information was available (n = 21) and using a published method of estimation when not available (n = 24), and was available for 45 patients. Results: A statistically significant decrease in testosterone, though small in magnitude, was seen at 6 months after completion of therapy, with no significant difference by 1 year after completion of therapy. There was no increase in biochemical hypogonadism after IMRT. Below-normal pretreatment testosterone was not associated with a transient decrease. Estimated cumulative testicular dose, including dose from daily imaging, was not associated with a change in testosterone, nor was radiation therapy prescription dose or treatment intent (postoperative vs definitive). Conclusions: The mild transient decrease in serum testosterone following IMRT monotherapy for prostate cancer is not associated with new biochemical hypogonadism.",
author = "Stephanie Markovina and Weschenfelder, {D{\'e}bora Cristina} and Hiram Gay and Audrey McCandless and Bethany Carey and Todd DeWees and Nels Knutson and Jeff Michalski",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.prro.2014.02.004",
language = "English (US)",
volume = "4",
pages = "430--436",
journal = "Practical Radiation Oncology",
issn = "1879-8500",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Low incidence of new biochemical hypogonadism after intensity modulated radiation therapy for prostate cancer

AU - Markovina, Stephanie

AU - Weschenfelder, Débora Cristina

AU - Gay, Hiram

AU - McCandless, Audrey

AU - Carey, Bethany

AU - DeWees, Todd

AU - Knutson, Nels

AU - Michalski, Jeff

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose: To evaluate serum testosterone and the incidence of biochemical hypogonadism in men treated with intensity modulated radiation therapy (IMRT) for prostate cancer. Methods and materials: Serum testosterone was evaluated prospectively in 51 men at pretreatment and at 6-month time points for 2 years posttreatment with IMRT for prostate cancer. Forty-one patients (80%) were treated with definitive intent and 10 patients with postprostatectomy radiation to median total doses of 7380 cGy and 6480 cGy, respectively. No patients received hormone therapy within 12 months of any serum testosterone value. Biochemical hypogonadism was defined as a total serum testosterone level ≤. 300 ng/dL. Incidental testicular dose was calculated using planning software when computed tomography information was available (n = 21) and using a published method of estimation when not available (n = 24), and was available for 45 patients. Results: A statistically significant decrease in testosterone, though small in magnitude, was seen at 6 months after completion of therapy, with no significant difference by 1 year after completion of therapy. There was no increase in biochemical hypogonadism after IMRT. Below-normal pretreatment testosterone was not associated with a transient decrease. Estimated cumulative testicular dose, including dose from daily imaging, was not associated with a change in testosterone, nor was radiation therapy prescription dose or treatment intent (postoperative vs definitive). Conclusions: The mild transient decrease in serum testosterone following IMRT monotherapy for prostate cancer is not associated with new biochemical hypogonadism.

AB - Purpose: To evaluate serum testosterone and the incidence of biochemical hypogonadism in men treated with intensity modulated radiation therapy (IMRT) for prostate cancer. Methods and materials: Serum testosterone was evaluated prospectively in 51 men at pretreatment and at 6-month time points for 2 years posttreatment with IMRT for prostate cancer. Forty-one patients (80%) were treated with definitive intent and 10 patients with postprostatectomy radiation to median total doses of 7380 cGy and 6480 cGy, respectively. No patients received hormone therapy within 12 months of any serum testosterone value. Biochemical hypogonadism was defined as a total serum testosterone level ≤. 300 ng/dL. Incidental testicular dose was calculated using planning software when computed tomography information was available (n = 21) and using a published method of estimation when not available (n = 24), and was available for 45 patients. Results: A statistically significant decrease in testosterone, though small in magnitude, was seen at 6 months after completion of therapy, with no significant difference by 1 year after completion of therapy. There was no increase in biochemical hypogonadism after IMRT. Below-normal pretreatment testosterone was not associated with a transient decrease. Estimated cumulative testicular dose, including dose from daily imaging, was not associated with a change in testosterone, nor was radiation therapy prescription dose or treatment intent (postoperative vs definitive). Conclusions: The mild transient decrease in serum testosterone following IMRT monotherapy for prostate cancer is not associated with new biochemical hypogonadism.

UR - http://www.scopus.com/inward/record.url?scp=84912527559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912527559&partnerID=8YFLogxK

U2 - 10.1016/j.prro.2014.02.004

DO - 10.1016/j.prro.2014.02.004

M3 - Article

C2 - 25407866

AN - SCOPUS:84912527559

VL - 4

SP - 430

EP - 436

JO - Practical Radiation Oncology

JF - Practical Radiation Oncology

SN - 1879-8500

IS - 6

ER -